Pulmonary vascular resistance predicts the mortality in patients with bronchiectasis-associated pulmonary hypertension

Jian Xu,Jing-jing Wang,Qin-hua Zhao,Su-gang Gong,Wen-hui Wu,Rong Jiang,Ci-jun Luo,Hong-ling Qiu,Hui-ting Li,Lan Wang,Jin-ming Liu
DOI: https://doi.org/10.1097/hjh.0000000000003782
IF: 4.9
2024-08-29
Journal of Hypertension
Abstract:Pulmonary hypertension associated with lung diseases and/or hypoxia accounts for a significant proportion of pulmonary hypertension cases [1–3] . Mild pulmonary hypertension is commonly observed in advanced parenchymal and interstitial lung disease, with 1–5% of patients with advanced chronic obstructive pulmonary disease (COPD) or candidates for lung volume reduction surgery or lung transplantation having a mean pulmonary arterial pressure (mPAP) at least 35–40 mmHg, which is indicative of poor prognosis [4–7] . In idiopathic pulmonary fibrosis, initial investigation has reported an mPAP at least 25 mmHg in 8–15% of patients, with higher prevalence seen in advanced (30–50%) and end-stage (>60%) disease stages [5,8] . Additionally, bronchiectasis, a clinical syndrome characterized by abnormal thickening and dilation of the bronchial wall, can contribute to cardiac dysfunction and pulmonary hypertension [9–11] . The prevalence of pulmonary hypertension among individuals with bronchiectasis ranges from 33 to 48%, as defined by a systolic pulmonary arterial pressure (sPAP) at least 36 mmHg on Doppler echocardiography [10,12,13] . Furthermore, bronchiectasis participants with pulmonary hypertension have poorer survival rates compared with those without pulmonary hypertension [11] .
peripheral vascular disease
What problem does this paper attempt to address?